This transgenic line expresses the human ERBB2 (HER2) gene in mammary gland and brain, displays tolerance to ERBB2 antigen and may be useful in testing ERBB2-based vaccines and immunotherapies.
Technology Summary
Her-2 positive breast cancer is a breast cancer that is positive for a protein called human epidermal growth factor receptor 2 (Her-2). Presence of Her-2 promotes the growth of cancer cells and is caused by a genetic mutation. 1 in 5 breast cancers are labelled as Her-2 positive; these types of cancers tend to be more aggressive and less responsive to hormone treatment.
This technology is an animal model designed to help pharmaceutical and biotechnology industries develop Her-2 based vaccines or immunotherapeutic agents.
Key Advantages
- Animals tolerant to Her-2 and exhibit immune responses similar to those seen in humans
Market Opportunities
Available under LEAP license
- B6.Cg-Pds5bTg(Wap-ERBB2)229Wzw/J
Stage of Development
Pre-Clinical
References & Publications
Piechocki, M.P., Ho, Y.S., Pilon, A. and Wei, W.Z. Human ErbB-2 (Her-2) transgenic mice: A model system for testing Her-2 based vaccines, J. Immunol. 171: 5787-5794, 2003.
